| Pexelizumab | acute myocardial infarction, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Serious infection | 0.90 [0.64 1.26] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | All cause death | 0.94 [0.75 1.19] | p=1.00 | 0 | 7019 | 3 | APEX-AMI, COMMA, COMPLY, | | Major bleeding | 1.01 [0.53 1.91] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, |
| Trial | Studied treatment | Control | Patients |
|---|
| APEX-AMI, 2007 | pexelizumab given as a 2-mg/kg intravenous bolus prior to PCI followed by 0.05-mg/kg per hour infusion over the subsequent 24 hours | placebo | primary angioplasty fo high risk STEMI | | COMMA, 2003 | pexelizumab 2.0-mg/kg bolus and 0.05-mg/kg per h infusion for 20 hours | placebo | patients with MI | | COMPLY, 2003 | pexelizumab 2.0-mg/kg bolus plus 0.05 mg/kg per h for 20 hours | placebo | patients with acute ST-segment elevation myocardial infarction receiving fibrinolysis |
| |
| Pexelizumab | acute myocardial infarction, in patient undergoing primary angioplasty | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Serious infection | 0.90 [0.64 1.26] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | All cause death | 1.04 [0.79 1.35] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, | | Major bleeding | 1.01 [0.53 1.91] | p=1.00 | 0 | 5745 | 1 | APEX-AMI, |
| Trial | Studied treatment | Control | Patients |
|---|
| APEX-AMI, 2007 | pexelizumab given as a 2-mg/kg intravenous bolus prior to PCI followed by 0.05-mg/kg per hour infusion over the subsequent 24 hours | placebo | primary angioplasty fo high risk STEMI |
| |
